Piramal Pharma Limited
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is headquartered in Mumbai, India, with significant operations across North America, Europe, and Asia. Founded in 1988, the company has established itself as a leader in both contract development and manufacturing, as well as in the production of complex generics and specialty pharmaceuticals. Piramal Pharma's core offerings include a diverse range of products, such as injectable formulations, oral solids, and advanced drug delivery systems, distinguished by their innovative approaches and high-quality standards. The company has achieved notable milestones, including strategic partnerships and expansions that have solidified its market position. With a commitment to enhancing patient outcomes, Piramal Pharma continues to drive advancements in healthcare, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Piramal Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Limited's score of 32 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Piramal Pharma Limited's reported carbon emissions
In 2023, Piramal Pharma Limited reported total carbon emissions of approximately 450,639,000 tonnes CO2e, comprising 55,229,000 tonnes CO2e from Scope 1, 75,494,000 tonnes CO2e from Scope 2, and 450,639,000 tonnes CO2e from Scope 3 emissions. This represents a slight decrease in total emissions compared to 2022, where emissions were about 477,407,000 tonnes CO2e. The company has made commitments to reduce its carbon footprint, with a near-term target status classified as "Committed." However, it has not set a net-zero target or specified a long-term reduction goal. The emissions intensity for Scope 1 and Scope 2 combined is reported at approximately 2.85 micrograms per rupee of turnover, indicating a focus on improving efficiency alongside emissions reductions. Piramal Pharma's emissions profile highlights the significant impact of Scope 3 emissions, which account for the majority of their carbon footprint, particularly from purchased goods and services, and the use of sold products. The company is actively working towards enhancing its sustainability practices within the pharmaceutical sector, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 56,578,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 85,844,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 477,407,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Piramal Pharma Limited is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
